skin penetration is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Dry, protected from light |
| Appearance in solution | Blue | Tone varies with pH and concentration |
| Primary analytical method | LC-MS with ICP-MS | Identity plus copper content |
| pH sensitivity | Higher near neutral and above | Alkaline conditions can degrade it |
| Common supplied form | Freeze-dried solid | Dissolved before use |
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
== Adverse effects == Very common (greater than 10% of people experience them) adverse effects include upper respiratory tract infections. Common (between 1% and 10% of people experience them) include oral herpes, runny nose, and diarrhea. Injection site reactions are common, occurring in approximately 1.9% of cases. In clinical trials there were rare instances of hypersensitivity reactions, severe infections, and some cases of serious inflammatory bowel disease, some of which were new and some of which were exacerbations of existing conditions. Caution should be used when starting secukinumab in patients with inflammatory bowel disease, and patients being treated with secukinumab should be monitored for signs and symptoms of inflammatory bowel disease.
Meanwhile, the regulatory approach favored by Liu would help maintain points of contact between Han and indigenous people, and, according to Wang Zhuo, would make them "more accustomed to Hanization." Liu did not personally reiterate those statements, although this was an argument presented by his faction and criticized by their opponents. In the end, Liu's side prevailed, and wula would not be fully abolished until the establishment of communist rule decades later. Liu did abolish several minor corvée duties, including the provision of firewood, fodder, tea, and miscellaneous services such as sweeping, but these were distinct from the transport corvée. Liu defended the wula system's continued existence in a 1939 conference: "if the people think the corvée is an oppressive policy, then they are wrong." Liu's 1990 biography mentions this as emblematic of the limits of warlord-driven reform compared to the wula's complete abolition under Mao in 1959.
Clinical trials designed by a local investigator, and (in the US) federally funded clinical trials, are almost always administered by the researcher who designed the study and applied for the grant. Small-scale device studies may be administered by the sponsoring company. Clinical trials of new drugs are usually administered by a contract research organization (CRO) hired by the sponsoring company. The sponsor provides the drug and medical oversight. A CRO is contracted to perform all the administrative work on a clinical trial. For phases II–IV the CRO recruits participating researchers, trains them, provides them with supplies, coordinates study administration and data collection, sets up meetings, monitors the sites for compliance with the clinical protocol, and ensures the sponsor receives data from every site. Specialist site management organizations can also be hired to coordinate with the CRO to ensure rapid IRB/IEC approval and faster site initiation and patient recruitment. Phase I clinical trials of new medicines are often conducted in a specialist clinical trial clinic, with dedicated pharmacologists, where the subjects can be observed by full-time staff. These clinics are often run by a CRO which specialises in these studies. At a participating site, one or more research assistants (often nurses) do most of the work in conducting the clinical trial.
Sources: en.wikipedia.org
=== Antihypertensive medicines === Amlodipine Bisoprolol Enalapril Hydralazine Hydrochlorothiazide Lisinopril/amlodipine (lisinopril + amlodipine) Lisinopril/hydrochlorothiazide (lisinopril + hydrochlorothiazide) Losartan Methyldopa Perindopril/amlodipine/indapamide (perindopril + amlodipine + indapamide) Telmisartan/amlodipine (telmisartan + amlodipine) Telmisartan/hydrochlorothiazide (telmisartan + hydrochlorothiazide) Valsartan/amlodipine/hydrochlorothiazide (valsartan + amlodipine + hydrochlorothiazide) Complementary:
In chemical analysis, chromatography is a laboratory technique for the separation of a mixture into its components. The mixture is dissolved in a fluid solvent (gas or liquid) called the mobile phase, which carries it through a system (a column, a capillary tube, a plate, or a sheet) on which a material called the stationary phase is fixed. As the different constituents of the mixture tend to have different affinities for the stationary phase and are retained for different lengths of time depending on their interactions with its surface sites, the constituents travel at different apparent velocities in the mobile fluid, causing them to separate. The separation is based on the differential partitioning between the mobile and the stationary phases. Subtle differences in a compound's partition coefficient result in differential retention on the stationary phase and thus affect the separation. Chromatography may be preparative or analytical. The purpose of preparative chromatography is to separate the components of a mixture for later use, and is thus a form of purification. This process is associated with higher costs due to its mode of production. Analytical chromatography is done normally with smaller amounts of material and is for establishing the presence or measuring the relative proportions of analytes in a mixture. The two types are not mutually exclusive.
=== Mammoth === MAMMOTH approaches the alignment problem from a different objective than almost all other methods. Rather than trying to find an alignment that maximally superimposes the largest number of residues, it seeks the subset of the structural alignment least likely to occur by chance. To do this it marks a local motif alignment with flags to indicate which residues simultaneously satisfy more stringent criteria: 1) Local structure overlap 2) regular secondary structure 3) 3D-superposition 4) same ordering in primary sequence. It converts the statistics of the number of residues with high-confidence matches and the size of the protein to compute an Expectation value for the outcome by chance. It excels at matching remote homologs, particularly structures generated by ab initio structure prediction to structure families such as SCOP, because it emphasizes extracting a statistically reliable sub alignment and not in achieving the maximal sequence alignment or maximal 3D superposition. For every overlapping window of 7 consecutive residues it computes the set of displacement direction unit vectors between adjacent C-alpha residues. All-against-all local motifs are compared based on the URMS score. These values become the pair alignment score entries for dynamic programming which produces a seed pair-wise residue alignment.
Liesegang: in 1927, he placed filter strips in closed containers with atmospheres saturated by solvents, and in 1943 he began using discrete spots of sample adsorbed to filter paper, dipped in pure solvent to achieve separation. This method, essentially identical to modern paper chromatography, was published just before the independent—and far more influential—work of Archer Martin and his collaborators that inaugurated the widespread use of paper chromatography. In 1897, the American chemist David Talbot Day (1859–1915), then serving with the U.S. Geological Survey, observed that crude petroleum generated bands of color as it seeped upwards through fine-grained clay or limestone. In 1900, he reported his findings at the First International Petroleum Congress in Paris, where they created a sensation.
Sources: en.wikipedia.org
== Signs and symptoms == The key sign of metabolic syndrome is central obesity, also known as visceral, male-pattern or apple-shaped adiposity. It is characterized by adipose tissue accumulation predominantly around the waist and trunk. Other signs of metabolic syndrome include high blood pressure, decreased fasting serum HDL cholesterol, elevated fasting serum triglyceride level, impaired fasting glucose, insulin resistance, or prediabetes. Associated conditions include hyperuricemia; fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease; polyendocrine metabolic ovarian syndrome in women and erectile dysfunction in men; and acanthosis nigricans.
==== Animal ==== Progesterone is produced in high amounts in the ovaries (by the corpus luteum) from the onset of puberty to menopause. The hormone is produced in smaller amounts by the adrenal glands after the onset of adrenarche in both males and females. To a lesser extent, progesterone is produced in nervous tissue, especially in the brain, and also in adipose tissue (fat). During human pregnancy, progesterone is produced in increasingly high amounts by the ovaries and placenta. At first, the source is the corpus luteum that has been "rescued" by the presence of human chorionic gonadotropin (hCG) from the conceptus. However, after the eighth week, production of progesterone shifts to the placenta which uses maternal cholesterol as the initial substrate, and most of the produced progesterone enters the maternal circulation, but some is picked up by the fetal circulation and used as substrate for fetal corticosteroids. At term, the placenta produces about 250 mg progesterone per day. An additional animal source of progesterone is milk products. After consumption of milk products the level of bioavailable progesterone goes up.
=== Alprostadil === Alprostadil is used for two main purposes: the treatment of newborns with congenital heart defects and in treatment of erectile dysfunction. Some babies are born with heart defects which compromise blood flow to the body. In some defects, including tetralogy of Fallot, aortic valvular atresia, and Eisenmenger pulmonary hypertension, alprostadil is given intravenously by a nurse until surgery can be performed to repair the defect. The medication maintains a patent ductus arteriosus. The ductus arteriosus is a shortcut between the aorta and pulmonary artery, two large vessels branching off the heart. This shortcut allows the fetus to maintain blood flow before birth. However, it closes shortly after birth when the newborn can breathe oxygen. In babies with certain congenital defects, however, it's essential to keep the ductus arteriosus open to ensure at least some blood flow throughout the body. Side effects include decreased breathing or a lack of breathing at high doses. The medication can also cause hypotension, or low blood pressure. Alprostadil is also used for adults with erectile dysfunction. It is typically given when other medications are ineffective. The medication relaxes smooth muscle and allows the arteries in the corpus cavernosum of the penis to dilate. Blood then flows to the penis. This blood flow compresses the veins which drain blood from the penis, trapping the blood in the corpus cavernosum. This process leads to erection.
=== 1975 === January 3: The Trade Act of 1974, including the Jackson–Vanik amendment, is signed into law in the United States. April 13: Tensions between the Maronite Christians and Muslims ignited the Lebanese Civil War. April 18: The communist Khmer Rouge, under the leadership of Pol Pot, take power in Cambodia. Beginning of the Cambodian genocide. April 30: North Vietnam wins the Vietnam War. The South Vietnam regime falls with the surrender of Saigon and the two countries are later united under a communist government. May 12: Mayagüez incident: the Khmer Rouge seize an American naval ship, prompting American intervention to recapture the ship and its crew. In the end, the crew is released from captivity. June 8: Venera 9, a Soviet uncrewed space mission to Venus, is launched. June 25: Portugal withdraws from Angola and Mozambique, where Marxist governments are installed, the former with backing from Cuban troops. Civil war engulfs both nations and involves Angolans, Mozambicans, South Africans, and Cubans, with the superpowers supporting their respective ideologies. July 5: Cape Verde becomes independent from Portugal. July 6: Comoros becomes independent from France. July 12: São Tomé and Príncipe becomes independent from Portugal. July 15: The Apollo-Soyuz Test Project takes place. It is the first joint flight of the US and Soviet space programs. The mission is seen as a symbol of détente and an end to the "space race".
Seventeen yachts and 167 crew started the first race of 27,500 nmi (50,900 km), which began from Portsmouth, United Kingdom, on 8 September 1973. Approximately 3000 spectator boats set out to witness the historic start. The first race was won by Mexican amateur Ramón Carlín in a Swan 65 yacht, Sayula II. Sayula II was followed by Adventure, Grand Louis and Kriter. The original course was designed to follow the route of the square riggers, which had carried cargo around the world during the 19th Century. From 2001 the ownership of the race was taken over by Volvo and Volvo Cars and the race was renamed the 'Volvo Ocean Race'. Stopover ports were added in Germany, France, and Sweden being Volvo's three biggest car markets in Europe. Winning the race does not attract a cash prize, as the feat of competing is presented as sufficient reward. Many of the crew in the Volvo Ocean Race race crew other professional teams in other high-profile events, such as the Olympic Games, Sydney to Hobart Yacht Race, the America's Cup, or the Fastnet Race. The worst weather conditions are usually encountered in the Southern Ocean where waves sometimes top 150 feet (46 m) and winds can reach 70 knots (130 km/h). The 2017–18 race covered 45,000 nautical miles, which is the longest route in its history.
Sources: en.wikipedia.org
Freezer temperatures are common for long-term retention. Light and moisture exposure should be limited. Working portions are best kept cold and used without repeated freeze-thaw cycles.
Sequence assays confirm the amino acids but say nothing about the metal. Copper content links the peptide to the ion that defines the complex. An elemental technique is used for this step.
No. Several copper species and degraded mixtures can also look blue. Confirmation needs both separation data and elemental data.
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.